No Clinical Benefit of LY-CoV555 Antibodies Plus Remdesivir in Hospitalized COVID-19 Patients

N Engl J Med. 2021 11-Mar;():. 10.1056/NEJMoa2033130

Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19

N Engl J Med. 2020 Oct 28;():. 10.1056/NEJMoa2029849

Juvenile RA: Fewer disease flares with Adalimumab (TNF Antibody)

N Engl J Med. 2008 Aug 21;359(8):810-20

Tocilizumab treatment in systemic juvenile idiopathic arthritis

N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802

Long-term safety and effectiveness of tanezumab 10 mg vs. 20 mg for chronic low back pain

Pain. 2014 Sep;155(9):1793-801.

Tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee

Osteoarthritis Cartilage; 2011;19(12):1405-1412

Tanezumab effectively and safely reduces OA hip pain and improves physical function

Arthritis Rheum. 2013 Jul;65(7):1795-803. doi: 10.1002/art.37950

Lower incidence of vertebral fracture with romosozumab vs placebo for osteoporosis

N Engl J Med. 2016 Oct 20;375(16):1532-1543

Romosozumab versus placebo, alendronate, and teriparatide for postmenopausal osteoporosis

Climacteric. 2018 Apr;21(2):189-195

Diclofenac, ibuprofen, and celecoxib improve function and pain in knee OA patients

Osteoarthritis Cartilage. 2013 Sep;21(9):1400-8

Golimumab treatment provides superior treatment of rheumatoid arthritis

Lancet. 2009 Jul 18;374(9685):210-21. Epub 2009 Jun 26

CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis

Arthritis Res Ther. 2016 Jan 20;18(1):25

Efficacy of tanezumab vs. placebo on pain, function, safety for patients with knee OA

PLoS One. 2016 Jun 13;11(6):e0157105.

WCO-IOF 2016: Greater BMD increase after 1 year of romosozumab vesus teripratide

Greater BMD increase with denosumab vs ZOL in patients switching from oral bisphosponates

J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70

Canakinumab effective in treating systemic juvenile idiopathic arthritis

N Engl J Med. 2012 Dec 20;367(25):2396-406. doi: 10.1056/NEJMoa1205099

Romosozumab has no impact on radiographic or clinical outcomes following hip fracture ORIF

J Bone Joint Surg Am. 2020 ;():. 10.2106/JBJS.19.00790

Reduction in Odds of Pathological Fracture with Denosumab vs Zoledronic Acid for Bone Metastases

J Am Acad Orthop Surg Glob Res Rev. 2020 Aug-01;():. 10.5435/JAAOSGlobal-D-20-00045

Salmon calcitonin appears ineffective in the management of knee OA treatment in 2 RCTs

Osteoarthritis Cartilage. 2015 Apr;23(4):532-43.

Similar Outcomes With Native Vitamin D and Eldecalcitol in Osteoporotic Women Taking Denosumab

Prog Rehabil Med. 2020 October 30,2020;():. 10.2490/prm.20200026